<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02617043</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-BC001</org_study_id>
    <nct_id>NCT02617043</nct_id>
  </id_info>
  <brief_title>Hypofractionated Whole-breast Irradiation With Simultaneously Integrated Boost For Early-Stage Breast Cancer After Breast-conserving Surgery</brief_title>
  <acronym>HF-WBI-SIB</acronym>
  <official_title>Hypofractionated Whole-breast Irradiation With Simultaneously Integrated Boost For Early-Stage Breast Cancer After Breast-conserving Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed to evaluate the feasibility and safety of hypofractionated
      whole-breast irradiation with simultaneously integrated boost for early-stage breast cancer
      after breast conserving surgery in Chinese population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of participants with treatment-related toxicity assessed by CTCAE v4.0</measure>
    <time_frame>2 year</time_frame>
    <description>acute toxicity related to irradiation such as lung and skin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute radiation-induced toxicity assessed by CTCAE v4.0</measure>
    <time_frame>during radiotherapy; 3months; 6 months</time_frame>
    <description>acute toxicity related to skin and lung</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local-regional recurrence</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival Over survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late complications</measure>
    <time_frame>1,2,3,4,5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cosmetic effect measured by Harvard 4 scale evaluation system</measure>
    <time_frame>2,3,4,5years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>HF-WBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated whole breast irradiation for early breast cancer with prescription dose 40Gy in 15 fractions in 3 weeks. Tumor bed is simultaneously integrated boosted to 48Gy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated whole breast irradiation with simultaneously integrated boost</intervention_name>
    <description>deliver 40Gy/15Fx to whole breast with 48Gy/15fx simultaneously integrated to tumor bed</description>
    <arm_group_label>HF-WBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  18-60 years old

          -  Treated with breast conversing surgery and sentinel lymph node biopsy or axillary
             lymph node dissection

          -  Pathologically confirmed invasive breast cancer

          -  A pathological T1-2N0M0 tumor

          -  Tumor bed is labeled with Titanium clips

          -  Negative surgical margins

          -  Written informed consent.

        Exclusion Criteria:

          -  KPSï¼œ70

          -  Treated with neoadjuvant chemotherapy

          -  Sentinel lymph nodes only containing isolated tumour cells (&lt;0.2 mm)

          -  With severe comorbidity

          -  Previous breast cancer or other malignant tumor history

          -  Previous radiotherapy for breast or thorax

          -  Medical contraindication for radiotherapy

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoli Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoli Yu, MD</last_name>
    <phone>+86 13817893133</phone>
    <email>stephanieyxl@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoli Yu, MD,PhD</last_name>
      <phone>+86 13817893133</phone>
      <email>stephanieyxl@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jurui Luo, MD</last_name>
      <phone>+86 13162996951</phone>
      <email>juruiluo@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>November 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xiaoli Yu</investigator_full_name>
    <investigator_title>Associate Professor of department of radiation oncology</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>hypofractionated whole breast irradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

